AR028826A1 - Compuestos que inhiben carboxipeptidasas, un proceso para su preparacion, una formulacion farmaceutica que los contiene y uso de los mismos para la fabricacion de un medicamento - Google Patents

Compuestos que inhiben carboxipeptidasas, un proceso para su preparacion, una formulacion farmaceutica que los contiene y uso de los mismos para la fabricacion de un medicamento

Info

Publication number
AR028826A1
AR028826A1 ARP000102082A ARP000102082A AR028826A1 AR 028826 A1 AR028826 A1 AR 028826A1 AR P000102082 A ARP000102082 A AR P000102082A AR P000102082 A ARP000102082 A AR P000102082A AR 028826 A1 AR028826 A1 AR 028826A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkylaryl
halogen
compounds
inhibit
Prior art date
Application number
ARP000102082A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR028826A1 publication Critical patent/AR028826A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos de la formula (1) y sales farmacéuticamente aceptables de los mismos, que inhiben carboxipeptidasas, en donde R1 representa H, OH, halogeno, alquilo C1-6, alquilarilo C1-6, alcoxi C1-6, ciano, NO2, SHN(R8)2 o COûalquilo C1-6, R2 representa H, OH, halogeno, o alquilo C1-6, R3 representa COOR6, SO2R6, SO3R6, P=O(OR6)2, B(OR6)2, P=OR6(OR6), tetrazol o cualquier isostero de ácido carboxílico, R4 representa un grupo de formulas (2), (3) o (4); R5 representa H, OH, halogeno, alquilo C1-6, alquilarilo C1-6, alcoxi C1-6, ciano, NO2, SHN(R8)2 o COûalquilo C1-6, R6 representa H, o alquilo C1-6, alquilarilo C1-6, o arilo, R7 representa un dipéptido o un residuo aminoácido, ambos opcionalmente N û protegidos, R8 representa H, alquilo C1-6, o alquilarilo C1-6, R9 representa H, o alquilo C1-6, alquilarilo C1-6, o arilo, R10 representa H, OH, halogeno, alquilo C1-6, alquilarilo C1-6, alcoxi C1-6, ciano, NO2, SHN(R8)2 o COûalquilo C1-6, X representa O, S, CH2, CH2CH2, CH2CH2CH2, NH, CH(Z), o N(Z), Y representa O, CH2, o CH (Z), o un enlace simple, Z representa alquilo C1-6, o alquilarilo C1-6, y Het representa un grupo heterocíclico alifático o aromático de 4, 5 o 6 miembros, que contiene por lo menos un átomo de nitrogeno, oxígeno o azufre, un grupo carbocíclico alifático o aromático de 4, 5 o 6 miembros o un enlace simple; un proceso para su preparacion; una formulacion farmacéutica que los contiene y el uso de los mismos para la fabricacion de un medicamento. Los compuestos se pueden usar en consecuencia en la prevencion y tratamiento de enfermedades asociadas con las carboxipeptidasa U.
ARP000102082A 1999-05-03 2000-04-28 Compuestos que inhiben carboxipeptidasas, un proceso para su preparacion, una formulacion farmaceutica que los contiene y uso de los mismos para la fabricacion de un medicamento AR028826A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9901572A SE9901572D0 (sv) 1999-05-03 1999-05-03 New compounds

Publications (1)

Publication Number Publication Date
AR028826A1 true AR028826A1 (es) 2003-05-28

Family

ID=20415425

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102082A AR028826A1 (es) 1999-05-03 2000-04-28 Compuestos que inhiben carboxipeptidasas, un proceso para su preparacion, una formulacion farmaceutica que los contiene y uso de los mismos para la fabricacion de un medicamento

Country Status (23)

Country Link
US (2) US7354895B1 (es)
EP (1) EP1180099A1 (es)
JP (1) JP4270759B2 (es)
KR (1) KR20020010631A (es)
CN (1) CN1358187A (es)
AR (1) AR028826A1 (es)
AU (1) AU4447100A (es)
BR (1) BR0010256A (es)
CA (1) CA2371215A1 (es)
CZ (1) CZ20013931A3 (es)
EE (1) EE200100573A (es)
HK (1) HK1042493A1 (es)
HU (1) HUP0202379A3 (es)
IL (1) IL145953A0 (es)
IS (1) IS6141A (es)
MX (1) MXPA01011043A (es)
NO (1) NO20015374D0 (es)
PL (1) PL356140A1 (es)
SE (1) SE9901572D0 (es)
SK (1) SK15662001A3 (es)
TR (1) TR200103144T2 (es)
WO (1) WO2000066550A1 (es)
ZA (2) ZA200108966B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019836A1 (fr) * 1999-09-14 2001-03-22 Meiji Seika Kaisha, Ltd. Derives d'acides phosphoniques presentant une activite inhibitrice de carboxypeptidase b
SI1311488T1 (sl) * 2000-08-17 2010-01-29 Pfizer Ltd Substituirani imidazoli kot inhibitorji TAFIA
SE0103272D0 (sv) 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
CA2472239A1 (en) 2002-01-22 2003-07-31 Pfizer Inc. 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases
US6713496B2 (en) 2002-01-22 2004-03-30 Pfizer Inc 3-(imidazolyl)-2-alkoxypropanoic acids
CA2472238A1 (en) * 2002-01-22 2003-07-31 Pfizer Inc. 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
JP4472997B2 (ja) 2002-03-21 2010-06-02 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 血漿カルボキシペプチダーゼｂインヒビター
EP2361910A4 (en) 2008-10-29 2012-08-01 Taisho Pharmaceutical Co Ltd CONNECTION WITH TAFIA-INHIBITOR EFFECT
ES2960034T3 (es) * 2019-02-08 2024-02-29 Astrazeneca Ab Inhibidores de la arginasa y métodos de uso de los mismos
CN111110837B (zh) * 2020-01-06 2022-11-25 中国人民解放军陆军军医大学 一种羧肽酶抑制剂在制备预防重症致死性轮状病毒感染药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2516307A (en) * 1949-01-06 1950-07-25 Gen Mills Inc Vinyl resins plasticized with cyano esters
US4560680A (en) * 1982-03-15 1985-12-24 E. R. Squibb & Sons, Inc. Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors
US4849414A (en) * 1986-06-11 1989-07-18 E. R. Squibb & Sons, Inc. Substituted aminoalkanoylaminoalkyl phosphonate angiotensin converting enzyme inhibitors
FR2610951B1 (fr) * 1987-02-17 1989-05-05 Aerospatiale Armature tissee pour materiau composite
IL86951A (en) * 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
SK74594A3 (en) * 1991-12-17 1995-01-12 Procter & Gamble Pharma Treatment for treating of osteoporosis
US5550119A (en) * 1995-03-02 1996-08-27 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives as ECE inhibitors
US5672592A (en) * 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
JP3440305B2 (ja) * 1997-04-02 2003-08-25 高砂香料工業株式会社 ７−（ｎ−置換アミノ）−２−フェニルヘプタン酸 エステル誘導体及び該誘導体の製造方法
EA001742B1 (ru) 1997-02-27 2001-08-27 Американ Цианамид Компани N-гидрокси-2-(алкил-, арил- или гетероарилсульфанил, -сульфинил или -сульфонил)-3-замещенные алкилов, арилов или гетероариламидов в качестве ингибиторов матриксных металлопротеиназ
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
SE9901573D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
WO2001019836A1 (fr) * 1999-09-14 2001-03-22 Meiji Seika Kaisha, Ltd. Derives d'acides phosphoniques presentant une activite inhibitrice de carboxypeptidase b

Also Published As

Publication number Publication date
SE9901572D0 (sv) 1999-05-03
HUP0202379A2 (hu) 2002-12-28
KR20020010631A (ko) 2002-02-04
MXPA01011043A (es) 2002-06-04
CA2371215A1 (en) 2000-11-09
JP2002543179A (ja) 2002-12-17
IL145953A0 (en) 2002-11-10
IS6141A (is) 2001-11-01
US20060079484A1 (en) 2006-04-13
AU4447100A (en) 2000-11-17
EP1180099A1 (en) 2002-02-20
PL356140A1 (en) 2004-06-14
NO20015374L (no) 2001-11-02
WO2000066550A1 (en) 2000-11-09
CN1358187A (zh) 2002-07-10
EE200100573A (et) 2003-02-17
NO20015374D0 (no) 2001-11-02
US7423012B2 (en) 2008-09-09
ZA200108967B (en) 2003-01-30
TR200103144T2 (tr) 2004-11-22
ZA200108966B (en) 2003-01-30
WO2000066550A8 (en) 2001-01-25
SK15662001A3 (sk) 2002-09-10
US7354895B1 (en) 2008-04-08
HK1042493A1 (zh) 2002-08-16
CZ20013931A3 (cs) 2002-04-17
BR0010256A (pt) 2002-02-13
HUP0202379A3 (en) 2003-04-28
JP4270759B2 (ja) 2009-06-03

Similar Documents

Publication Publication Date Title
AR034241A1 (es) Compuestos que inhiben carboxipeptidasas, un proceso para su preparacion, una formulacion farmaceutica que los contiene y uso de los mismos para la fabricacion de un medicamento
HUP0401963A2 (hu) Karbonsavszármazékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények
AR025735A1 (es) Compuestos terapeuticos
HUP0202263A2 (hu) Benzimidazol-, indol- és imidazo-piridin-származékok és ezeket tartalmazó gyógyszerkészítmények
AR035320A1 (es) Compuestos activadores de hppardelta, composicion farmaceutica, su uso en la preparacion de medicamentos, metodo para el tratamiento de enfermedades mediadas por hppardelta
DE69205327D1 (de) Harnstoffderivate, Verfahren zu ihrer Herstellung und diese enthaltende Medikamente.
AR004219A1 (es) Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios
CY1109227T1 (el) Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων
HUP0004595A2 (hu) Aciklikus metalloproteáz inhibitorok
HUP0300262A2 (hu) Heterociklusos oldalláncot tartalmazó metalloproteáz inhibitorok
SE9203825L (sv) Dubbelt verkande inhibitorer foer no-syntas och cyklooxygenas, foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande desamma
ATE28565T1 (de) Spiro(4.(3+n))-2-aza-alkan-3-carbonsaeurederivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung.
AR028826A1 (es) Compuestos que inhiben carboxipeptidasas, un proceso para su preparacion, una formulacion farmaceutica que los contiene y uso de los mismos para la fabricacion de un medicamento
HUP0101381A2 (hu) Benzofurilpironszármazékok és ezeket tartalmazó gyógyszerkészítmények
IT1228293B (it) Benzoderivati di composti eterociclici contenenti azoto.
DZ1694A1 (fr) "n-(2-Aminoethyl)-benzothialozones".
DE3853577D1 (de) Benzyliden-Malononitril-Derivate zur Hemmung von proliferativen Prozessen in Säugetierzellen.
HUP0302770A2 (hu) Tripeptidil peptidáz inhibitorok, eljárás az előállítására és ezeket tartalmazó gyógyszerkészítmények
DE50011034D1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
CO4970807A1 (es) Compuestos de indol 2,3 sustituidos como agentes anti-infla matorios y analgesicos
AR012603A1 (es) Inhibidor de proteasa, composicion farmaceutica que lo comprende y el uso del mismo para la fabricacion de un medicamento; e intermediarios de sintesis
AR027296A1 (es) Derivados de 4-heteroaril-1,4-diazabiciclo[3.2.2]nonano, su preparacion y su aplicacion terapeutica
HUP0300235A2 (hu) Heterociklikus oldalláncot tartalmazó, N-szubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DK0952159T3 (da) Anvendelse af phenylhydrazonderivater som antiinflammatoriske eller analgetiske midler
DK537589D0 (da) Renininhiberende peptidasesubstratanaloge, hydrater, isostere eller farmaceutisk acceptable salte deraf

Legal Events

Date Code Title Description
FA Abandonment or withdrawal